FDA recall record

Astagraf XL recall — FDA D-0210-2025

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Class Iclassification
D-0210-2025official record ID
Feb 5, 2025report date

Recall record at a glance

Official recordD-0210-2025
CategoryDrug Recalls
ClassificationClass I
FDA record statusOngoing
Recalling firmAstellas Pharma US Inc.
Report dateFeb 5, 2025
Recall initiation dateDec 23, 2024
Quantity3,500 30-count bottles
LocationNorthbrook, IL, United States

Official product description

Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US Inc., Northbrook, IL 60062, NDC 0469-0647-73.

Why the product was recalled

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Distribution information

Nationwide in the USA

How to read the classification

FDA Class I indicates a situation in which there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. The classification shown here comes directly from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Press Release.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.